Researchers from the University of California (UC) Davis have been investigating whether two genetically engineered cell types could be customized for long term therapeutic benefit in individuals with hemophilia A.
Thirteen runners, nine states, thirteen miles, and one great cause: Team NHF are avid athletes who are excited to run on behalf of the bleeding disorders community.
The acquisition was approved on December 5th, 2018.
Linda Gammage, MSW, LCSW, passed away on December 26, 2018.
The court ruled that the entirety of the ACA is unconstitutional because the 2017 tax reform law eliminated the individual mandate tax penalty.
Sangamo announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational gene therapy for patients with hemophilia B.
Seven ways your gift to NHF will support people with bleeding disorders.
The data presented was from 33 patients who have completed five years of treatment with Jivi®.
The data from both studies confirmed the safety and sustained efficacy of Eloctate ® and Alprolix ® over four years of treatment.
NHF's research grants support a variety of disciplines and levels of expertise.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car